

Special Issue

Pyroptosis and Cellular Stress: Emerging Mechanisms and Therapeutic Targets

Message from the Guest Editor

This Special Issue, "Pyroptosis and Cellular Stress: Emerging Mechanisms and Therapeutic Targets", will focus on the molecular mechanisms underlying pyroptosis and its intricate relationship with various forms of cellular stress, as well as the therapeutic potential of modulating these pathways in inflammation, cancer, and immune-related diseases.

We invite authors to submit original research (basic, translational, or clinical) and review articles on the molecular regulation, pathophysiological roles, and therapeutic targeting of pyroptosis and cellular stress pathways. Potential topics include, but are not limited to:

- Crosstalk between pyroptosis and cellular stress signaling (ROS, mitochondrial stress, ER stress, etc.);
- The role of pyroptosis in cancer immunity, infection, inflammatory disease, or aging;
- Multi-omics and structural studies illuminating pyroptotic mechanisms;
- Impact of cellular metabolism and immunometabolism on inflammasome activation and pyroptotic responses;
- Inflammasome-independent pathways of inflammatory cell death and their pathological relevance.

Guest Editor

Dr. Gang Du

1. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
2. Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/247823

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).